Leading Nousom’s pipeline is off-the-shelf vaccine NOUS-209, which targets 209 shared neoantigens and is being tested alongside MSD’s checkpoint inhibitor Keytruda (pembrolizumab) in a phase 2 ...
Evercore ISI initiated coverage of Summit Therapeutics (SMMT) with an Outperform rating and $30 price target The firm sees lead asset, ...
Interim results from three trials exploring the use of Alpha DaRT® in treating pancreatic cancer showing high disease control rate, impressive ...
DelveInsight's "BAVENCIO Market Size, Forecast, and Market Insight Report" highlights the details around BAVENCIO, a human ...
With the rising adoption of checkpoint inhibitors and combination therapies, BAVENCIO's market growth is driven by expanding indications and strategic partnerships. However, competition from ...
MSD’s checkpoint inhibitor Keytruda has been cleared by the FDA for use in newly diagnosed cervical cancer patients with less severe disease, becoming the first anti-PD-1/PD-L1 immunotherapy for ...
It's time for another Market Cap Game Show. To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. To get started investing, check out our beginner's guide to ...
MarketBeat on MSN3d
Moderna: 4 Key Reasons the CEO Just Bought $5M in SharesCompanyOverview|NASDAQ:MRNA] The CEO of Moderna Inc. (NASDAQ: MRNA) just purchased $5 million of stock in the open market.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback